BENDER, Steven,CHARLTON, Tracy,GALKIN, Anna,GEIERSTANGER, Bernhard Hubert,GLASER, Scott Martin,KASIBHATLA, Shailaja,KNUTH, Mark,ROTTMANN, Sabine,RUE, Sarah,SPRAGGON, Glen,UNO, Tetsuo
申请号:
PE2019001507
公开号:
PE20191328A1
申请日:
2018.02.01
申请国别(地区):
PE
年份:
2019
代理人:
摘要:
1. It refers to a part of an antibody or polymer combined with human protein CCR7 (CC7 chemical receiver), which includes: a heavy chain variable region, including a seq-1 hexachlorobenzene, a seq-2 hexachlorobenzene and a seq-3 hexachlorobenzene; There is also a variable area of the light chain, including an SEC LCDR1 number of 17, an SEC LCDR2 number of 18, an SEC LCDR3 number of 19, etc. It also refers to a copolymer and an ab (L - (d) (m) n formula pharmacy, in which ab is the above antibody; L is a can; D is another pharmacy selected from v-atpasa inhibitor, a preservative, an inhibitor, etc.; m is 1-8;N from 1 to 12. The concentration of this antibody is very low, or there is no significant cytotoxic reaction at all. It depends on the antibody (ADCC) and suppresses the CCR7 expression in malignant tumors. It is useful in the treatment of cancer, such as chronic lymphocytic leukemia, non hodginiano lymphoma, lung cancer, etc.Referido a un anticuerpo o fragmento de union a antigeno que se une a la proteina CCR7 (receptor de quimioquina CC7) humana, que comprende: una region variable de cadena pesada que comprende un HCDR1 de SEQ ID NO: 1, un HCDR2 de SEQ ID NO: 2, y un HCDR3 de SEQ ID NO: 3; y una region variable de la cadena ligera que comprende una LCDR1 de SEC ID Nº: 17, una LCDR2 de SEC ID Nº: 18, una LCDR3 de SEQ ID NO: 19, entre otras. Tambien se refiere a un conjugado y un farmaco de formula Ab-(L-(D)m)n, donde: Ab es el anticuerpo anteriormente citado; L es un enlazador; D es un resto de farmaco seleccionado de un inhibidor de V-ATPasa, un agente proapoptotico, un inhibidor entre otros; m es de 1 a 8; y n es de 1 al 12. Dicho anticuerpo tiene un nivel reducido o ningun nivel significativo de actividad de citotoxicidad mediada por celulas dependiente de anticuerpo (ADCC) e inhibe la expresion de CCR7 presente en tumores malignos siendo util en el tratamiento de cancer como leucemia linfocitica cronica, linfoma no hodgkiniano, cancer de pulmon, entre otr